Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares traded down 1.5% on Friday . The stock traded as low as $65.02 and last traded at $65.29, with a volume of 263,346 shares traded. The stock had previously closed at $66.28.

Several research analysts have recently weighed in on the stock. Jefferies Group reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Sunday, July 17th. Canaccord Genuity reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Leerink Swann reaffirmed a “buy” rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, May 10th. Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Finally, Credit Suisse Group AG reaffirmed a “buy” rating and issued a $101.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Ultragenyx Pharmaceutical has an average rating of “Buy” and an average target price of $97.32.

The firm has a 50 day moving average price of $62.61 and a 200-day moving average price of $62.32. The stock’s market capitalization is $2.57 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($1.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.44) by $0.02. During the same quarter in the previous year, the company posted ($0.83) EPS. Equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current year.

In other news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $50.85, for a total transaction of $1,017,000.00. Following the sale, the chief executive officer now directly owns 513,597 shares in the company, valued at approximately $26,116,407.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sunil Agarwal sold 649 shares of the firm’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.